secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001933414-23-000090
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics presents new leptin analysis from Target-HTN trial of lorundrostat
--------------------------------------------------------------------------------

- Elevated BMI (>30 kg/m²) predicted enhanced systolic BP reduction: placebo-adjusted drops of 16.7 mmHg (50 mg) and 12.3 mmHg (100 mg).
- New analysis shows increased serum leptin correlates with higher BMI, suggesting leptin as a biomarker for responsive patients.
- Target-HTN results support transition to late-stage development; Advance-HTN pivotal trial enrolling, Launch-HTN expected H2 2023.
- Data presented at AHA Scientific Sessions 2023 in Philadelphia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/0001933414-23-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000090/mlys-20231111.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer